Bev Moir‘s career took her from ‘health’ care to ‘wealth’ care. After completing a nursing science degree at Queen’s University and a graduate degree in health administration at the University of Alberta, she spent 20 years in health care, primarily in academic tertiary care settings. During the early 1990s, she sought another opportunity and spent 26 years at Scotia Wealth Management, building and leading a wealth advisory practice.
In 2019, Bev was diagnosed with stage 4 non-small cell lung cancer (NSCLC) and given a life expectancy of six months to three years. As the reality hit, it’s not surprising her priorities shifted. By February 1, 2020, she successfully transitioned her practice to another Scotia Wealth advisor to spend her remaining time with family and friends doing what she enjoys.
Recent advances in cancer diagnostics and treatment help more cancer patients live longer and higher quality lives. Biomarker testing, an advanced diagnostic test, identifies patients eligible for therapies that more precisely and effectively target their tumour cells. As a result, patients experience fewer toxic side effects than conventional therapy, such as chemotherapy. As the grateful beneficiary of advanced biomarker testing at Sunnybrook Hospital, Bev now leads an active life and has lived beyond her ‘best before date.’
Bev’s will be discussing what made her an advocate, her team’s fundraising success and challenges, and the potential of funding to make a difference for those living with lung cancer. Dr. Alexander Louie will join her to supplement her patient experience with medical knowledge.
Anyone can get lung cancer; it should be on everyone’s radar.
Dr. Alexander Louie is a Clinician-Scientist in the Department of Radiation Oncology at Sunnybrook Health Sciences Centre and an Associate Professor of Radiation Oncology in the Temerty Faculty of Medicine at U of T. Dr. Louie is also a radiation oncologist at the London Regional Cancer Program (London Health Sciences Centre) and is cross appointed to the Department of Epidemiology & Biostatistics. Dr. Louie is also part of the Canadian Pulmonary Radiotherapy Investigators Group (CAPRI).
His research focuses on stereotactic ablative radiotherapy for lung cancer, selective treatment sparing techniques to improve patient outcomes and the development of clinical trials. His other areas of expertise include analysis of national cancer registry data and other population-based databases and the use of Markov modeling and cost effectiveness research to improve resource availability strategies. He has expertise in clinical trials, patient-reported outcomes, population databases, decision analyses, health economics and technological appraisals. As an avid educator and mentor to many research students, his goal is to motivate his students to take ownership of their projects to answer practical questions within Radiation Oncology.
- PhD cum laude, Lung SABR, Department of Radiation Oncology, VU University, Amsterdam,
- MSc, Epidemiology, Department of Epidemiology, Harvard School of Public Health
- MD, Schulich School of Medicine and Dentistry, Western University
- BSc with distinction, Department of Biology, Western University
- American Society of Clinical Oncology (ASCO)
- American Society of Radiation Oncology (ASTRO)
- International Association for the Study of Lung Cancer (IASLC)
- Canadian Association of Radiation Oncologists (CARO)
- Ontario Medical Association (OMA)
- The College of Physicians and Surgeons of Ontario
- The Royal College of Physicians and Surgeons of Canada
Join fellow Whiffers on Tuesday, January 31st
The reception at the RCYC begins at 6:00 pm.
The Whiff@Home Zoom meeting will open at ~7:30 pm for social conversation before the Speaker’s talk at ~8:15pm.
RSVPing open for Whiff@Home only
How to use Zoom